VA
LXEO icon

Verdad Advisers’s Lexeo Therapeutics LXEO Stock Holding History

Verdad Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
+30,591
New +$165K 0.14% 170

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Verdad Advisers's LXEO Position: Q2 2026 in Review

Verdad Advisers opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 30,591 shares worth $142K. The stake represents 0.14% of the portfolio and ranks #170 among its holdings.

142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Verdad Advisers held 30,591 shares of Lexeo Therapeutics worth $142K as of Q2 2026.
  • Lexeo Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Lexeo Therapeutics made up 0.14% of Verdad Advisers's portfolio in Q2 2026, its #170 holding.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.